Efficacy of in vitro sensitized cells generated by in vivo priming with OK-432 for adoptive immunotherapy of the poorly immunogenic B16-Bl6 melanoma.

doi:10.1016/0192-0561(95)00113-1

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Efficacy of in vitro sensitized cells generated by in vivo priming with OK-432 for adoptive immunotherapy of the poorly immunogenic B16-Bl6 melanoma.

International journal of immunopharmacology - 1 Feb 1996

Mukai S, Kato H, Kimura S, Asai K, Kawahito Y, Inoue M, Yamamura Y, Sano H, Sugino S, Shu S, Kondo M

Abstract excerpt

We investigated the efficacy of the streptococcal preparation OK-432 as an adjuvant for in vivo priming in induction of sensitized cells for adoptive immunotherapy of the poorly immunogenic B16-BL6 (BL6) melanoma. C57BL/6 (B6) mice were immunized subcutaneously (s.c.) with 3 x 10(6) viable BL6 tu...

Topics

Animals
Female
Immunization
Immunotherapy, Adoptive
Lung Neoplasms
Lymphoid Tissue
Melanoma, Experimental
Mice
Mice, Inbred C57BL
Phenotype
Picibanil
T-Lymphocytes
Tumor Cells, Cultured

Source

Open in PubMed

Identifiers

PMID: 8799364
DOI: 10.1016/0192-0561(95)00113-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-8799364-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics